Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
The closing price of Verve Therapeutics Inc (NASDAQ: VERV) was $5.25 for the day, up 9.83% from the previous closing price of $4.78. In other words, the price has increased by $9.83 from its previous closing price. On the day, 4.01 million shares were traded. VERV stock price reached its highest trading level at $5.305 during the session, while it also had its lowest trading level at $4.78.
Ratios:
Our analysis of VERV’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 12.65 and its Current Ratio is at 12.65. In the meantime, Its Debt-to-Equity ratio is 0.14 whereas as Long-Term Debt/Eq ratio is at 0.12.
On April 08, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $15.
On April 13, 2023, Canaccord Genuity started tracking the stock assigning a Buy rating and target price of $29.Canaccord Genuity initiated its Buy rating on April 13, 2023, with a $29 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Apr 02 ’25 when Kathiresan Sekar sold 9,822 shares for $4.15 per share. The transaction valued at 40,761 led to the insider holds 346,686 shares of the business.
Nickerson Joan sold 2,777 shares of VERV for $11,525 on Apr 02 ’25. The Chief Administrative Officer now owns 17,420 shares after completing the transaction at $4.15 per share. On Apr 02 ’25, another insider, Ashe Andrew D., who serves as the insider of the company, sold 2,681 shares for $4.15 each. As a result, the insider received 11,126 and left with 348,828 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VERV now has a Market Capitalization of 466177952 and an Enterprise Value of 11080620. For the stock, the TTM Price-to-Sale (P/S) ratio is 14.42 while its Price-to-Book (P/B) ratio in mrq is 0.94. Its current Enterprise Value per Revenue stands at 0.343 whereas that against EBITDA is -0.05.
Stock Price History:
The Beta on a monthly basis for VERV is 1.69, which has changed by -0.20212764 over the last 52 weeks, in comparison to a change of 0.042615533 over the same period for the S&P500. Over the past 52 weeks, VERV has reached a high of $9.31, while it has fallen to a 52-week low of $2.86. The 50-Day Moving Average of the stock is -8.80%, while the 200-Day Moving Average is calculated to be -10.96%.
Shares Statistics:
VERV traded an average of 2.65M shares per day over the past three months and 8653200 shares per day over the past ten days. A total of 88.76M shares are outstanding, with a floating share count of 66.12M. Insiders hold about 25.54% of the company’s shares, while institutions hold 69.99% stake in the company. Shares short for VERV as of 1743379200 were 16629900 with a Short Ratio of 6.28, compared to 1740700800 on 14864938. Therefore, it implies a Short% of Shares Outstanding of 16629900 and a Short% of Float of 22.16.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
At present, 10.0 analysts are actively evaluating the performance of Verve Therapeutics Inc (VERV) in the stock market.The consensus estimate for the next quarter is -$0.67, with high estimates of -$0.52 and low estimates of -$0.82.
Analysts are recommending an EPS of between -$2.02 and -$3.16 for the fiscal current year, implying an average EPS of -$2.66. EPS for the following year is -$2.67, with 9.0 analysts recommending between -$2.17 and -$3.11.
